Saturn V Capital Management LP — 13F Holdings & Portfolio
CIK 1964437 · latest 13F-HR filed 2026-08-14
Saturn V Capital Management LP manages $697.5M in 13F-reported U.S. long-equity assets across 23 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are AMLX (11.91%), ALMS (11.76%), ABVX (9.91%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 1; 16 existing positions rose in reported value and 3 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- AMYLYX PHARMACEUTICALS INC$22.6M +37.4%
- CANDEL THERAPEUTICS INC$19.8M +139.7%
- IMMIX BIOPHARMA INC$14.4M +42.7%
- PHARVARIS N V$11.5M +33.9%
- ALUMIS INC$11.5M +16.3%
Top Trims
- OVID THERAPEUTICS INC-$7.5M -80.7%
- INVIVYD INC-$6.9M -48.6%
- OCULIS HOLDING AG-$4.2M -30.9%
New Positions
- TREVI THERAPEUTICS INC$19.6M
- SAGIMET BIOSCIENCES INC$11.4M
- VIR BIOTECHNOLOGY INC$7.9M
Saturn V Capital Management LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $83.0M | 11.91% | 4,624,101 | SH |
| 2 | ALUMIS INC | ALMS | 022307102 | $82.0M | 11.76% | 2,915,443 | SH |
| 3 | ABIVAX SA | ABVX | 00370M103 | $69.1M | 9.91% | 518,865 | SH |
| 4 | VAXCYTE INC | PCVX | 92243G108 | $49.6M | 7.11% | 852,914 | SH |
| 5 | IMMIX BIOPHARMA INC | IMMX | 45258H106 | $48.0M | 6.89% | 4,658,429 | SH |
| 6 | PHARVARIS N V | PHVS | N69605108 | $45.4M | 6.52% | 1,314,122 | SH |
| 7 | JAZZ PHARMACEUTICALS PLC | JAZZ | G50871105 | $38.8M | 5.56% | 160,938 | SH |
| 8 | CELCUITY INC | CELC | 15102K100 | $38.7M | 5.55% | 370,318 | SH |
| 9 | DISC MEDICINE INC | IRON | 254604101 | $38.4M | 5.50% | 524,730 | SH |
| 10 | CANDEL THERAPEUTICS INC | CADL | 137404109 | $34.0M | 4.88% | 3,303,686 | SH |
| 11 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $32.6M | 4.67% | 6,973,343 | SH |
| 12 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $28.9M | 4.14% | 311,976 | SH |
| 13 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $23.5M | 3.37% | 1,057,493 | SH |
| 14 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $19.6M | 2.81% | 1,052,043 | SH |
| 15 | ZURA BIO LTD | ZURA | G9TY5A101 | $12.4M | 1.78% | 2,101,119 | SH |
| 16 | SAGIMET BIOSCIENCES INC | SGMT | 786700104 | $11.4M | 1.64% | 1,479,918 | SH |
| 17 | OCULIS HOLDING AG | OCS | H5870P102 | $9.5M | 1.36% | 684,880 | SH |
| 18 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $7.9M | 1.13% | 3,869,056 | SH |
| 19 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $7.9M | 1.13% | 770,643 | SH |
| 20 | INVIVYD INC | IVVD | 00534A102 | $7.3M | 1.05% | 8,392,288 | SH |
| 21 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $4.8M | 0.69% | 182,829 | SH |
| 22 | SATELLOS BIOSCIENCE INC | MSLE | 80401L803 | $2.7M | 0.39% | 350,000 | SH |
| 23 | OVID THERAPEUTICS INC | OVID | 690469101 | $1.8M | 0.26% | 663,060 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $697.5M | 23 | 0001964437-26-000012 |
| 2026-03-31 | 2026-05-15 | $552.2M | 21 | 0001964437-26-000005 |
| 2025-12-31 | 2026-02-17 | $544.9M | 20 | 0001964437-26-000003 |
| 2025-09-30 | 2025-11-14 | $456.0M | 17 | 0001964437-25-000013 |
SUITE 1030
AUSTIN, TX 78701-2102